异动解读 | 获纳入港股通及业绩改善,科济药业-B盘中大涨5.32%

异动解读
Mar 10

科济药业-B今日盘中大幅上涨5.32%,引起了市场的广泛关注。

消息面上,科济药业近期获重新纳入港股通标的,此举预计将吸引更多内地投资者,提升股票的流动性与市场关注度。同时,公司披露的2025年年报显示业绩显著改善,亏损额大幅收窄,增强了投资者信心。

具体而言,公司的BCMA CAR-T产品泽沃基奥仑赛注射液在2025年实现销售额1.26亿元,并通过与华东医药的合作有效控制了销售成本。此外,科济药业拥有国内CAR-T领域最丰富的在研管线之一,包括接近上市的CLDN18.2 CAR-T及多款处于临床早期的通用型CAR-T产品,展现了强大的长期研发潜力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10